Hey mate, results for the trial you are referring to finished in...

Hey mate, results for the trial you are referring to finished in May 2016, but there were comments at the AGM late last year about further work.

Could be value there. PBP owns the IP behind the treatment, and can offer it as a solution to contract manufacturing clients. From memory the phase two clinical results were really strong.

I haven't factored anything in, and with small cap biotechs things like these inevitably take longer than expected. But nice blue sky to have nonetheless, and the IP could potentially be sold if it is genuinely valuable and we can't maximise it.